NCT04806113View on ClinicalTrials.gov

COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

June 13, 2021

Study Completion Date

June 15, 2022

Conditions
Covid19Rheumatic DiseasesRheumatoid ArthritisSLE
Interventions
BIOLOGICAL

Moderna COVID-19 vaccine

Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.

Trial Locations (1)

H4A 3J1

McGill University Health Centre, Montreal

All Listed Sponsors
collaborator

CHU de Quebec-Universite Laval

OTHER

collaborator

Ministere de la Sante et des Services Sociaux

OTHER

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT04806113 - COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases | Biotech Hunter | Biotech Hunter